Wakayama Medical Center, Wakayama, Japan.
JACC Cardiovasc Interv. 2013 Jul;6(7):654-63. doi: 10.1016/j.jcin.2013.03.015.
This study assessed 5-year outcomes after implantation of sirolimus-eluting stents (SES) for unprotected left main coronary artery (ULMCA) disease in comparison with that for non-left main disease.
More information on long-term outcomes after ULMCA stenting is needed.
The j-Cypher is a multicenter prospective registry of consecutive patients undergoing SES implantation in Japan.
Among 12,812 patients enrolled in the j-Cypher registry, the unadjusted mortality rate at 5 years was significantly higher in patients with ULMCA stenting than in patients without ULMCA stenting (22.8% vs. 14.1%; p < 0.0001); however, the risk for death with ULMCA stenting was no longer significant after adjusting for confounders (hazard ratio: 1.18, 95% confidence interval: 0.95 to 1.46; p = 0.14). In the lesion-level comparison, the nonbifurcation ULMCA lesions treated exclusively with SES had a significantly lower rate of target lesion revascularization (TLR) than those in non-ULMCA nonbifurcation lesions (2.4% vs. 12.7%; p = 0.04). Among bifurcation lesions, those treated with a provisional 2-stent approach had similar rates of TLR (12.1% vs. 11.4%; p = 0.79) between the ULMCA and non-ULMCA groups. Lesions treated with an elective 2-stent approach had higher TLR rates in the ULMCA group as compared with the non-ULMCA group (33.5% vs. 19.7%; p = 0.002).
The safety of ULMCA stenting relative to non-LMCA stenting was maintained through 5 years follow-up. In terms of efficacy, SES implantation in nonbifurcation ULMCA lesions was associated with an extremely low cumulative incidence of TLR, whereas the elective 2-stent approach for ULMCA bifurcation lesions was associated with a markedly higher cumulative incidence of TLR as compared with that for non-ULMCA bifurcation lesions.
本研究旨在评估与非左主干病变相比,无保护左主干冠状动脉(ULMCA)疾病患者植入西罗莫司洗脱支架(SES)后 5 年的结果。
需要更多关于 ULMCA 支架置入后长期结果的信息。
j-Cypher 是一项多中心前瞻性登记研究,纳入了在日本接受 SES 植入术的连续患者。
在 j-Cypher 登记研究的 12812 例患者中,未校正的 5 年死亡率在接受 ULMCA 支架置入术的患者中明显高于未接受 ULMCA 支架置入术的患者(22.8% vs. 14.1%;p<0.0001);然而,在校正混杂因素后,ULMCA 支架置入术的死亡风险不再显著(风险比:1.18,95%置信区间:0.95 至 1.46;p=0.14)。在病变水平比较中,仅用 SES 治疗的非分叉 ULMCA 病变的靶病变血运重建(TLR)率明显低于非 ULMCA 非分叉病变(2.4% vs. 12.7%;p=0.04)。在分叉病变中,采用临时两支架方法治疗的病变在 ULMCA 组和非 ULMCA 组的 TLR 发生率相似(12.1% vs. 11.4%;p=0.79)。采用选择性两支架方法治疗的病变在 ULMCA 组的 TLR 发生率高于非 ULMCA 组(33.5% vs. 19.7%;p=0.002)。
在 5 年随访期间,与非 LMCA 支架置入术相比,ULMCA 支架置入术的安全性得以维持。在疗效方面,非分叉 ULMCA 病变植入 SES 与 TLR 的累积发生率极低相关,而 ULMCA 分叉病变采用选择性两支架方法与非 ULMCA 分叉病变相比,TLR 的累积发生率明显更高。